Drug
Ponatinib Phase 1
Ponatinib Phase 1: highest development phase Phase 1/2, developed by United Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- United Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| ponatinib - Phase 1 NCT01667133 | Phase 1/2 | Chronic Myeloid Leukemia (CML) |
Latest
No recent events.
Follow Ponatinib Phase 1 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.